Syncona Ltd GBP · LSE:SYNC
Syncona Ltd GBP — Syncona — Investor Presentation (March 2021)
39 slides from Syncona Ltd GBP's investor presentation, March 2021
Slide 1: Syncona Corporate presentation March 2021
Syncona Corporate presentation March 2021 synconaltd.com Image Freeline labs, Stevenage
Slide 2: Cautionary statement
Cautionary statement This presentation has been prepared and published solely for informational purposes. Nothing contained in this presentation is intended to constitute an offer, invitation or inducement to engage in an investment activity. In this statement, "presentation" means this document tog
Slide 3: Strategy and vision
Strategy and vision
Slide 4: Building the next generation of healthcare leaders
Building the next generation of healthcare leaders Founded in 2012 by The Wellcome Trust, our purpose is to invest to extend and enhance human life Globally significant Focus on products Founding companies Long-term, scientific research and patients with strategic ambitious capital base ownership Le
Slide 5: Capturing the out return in life science
Capturing the out return in life science +10 years Strategy designed to deliver strong risk adjusted returns for shareholders Syncona Traditional target Venture window Capital target exit window Out return in life science weighted towards late development and product approval: Value • Set companies
Slide 6: Delivering value through biotech company creation
Delivering value through biotech company creation Building sustainable companies and delivering transformational outcomes for patients Strong track record Building sustainable leaders Patient impact Gross IRR since Capital deployed since 2012 Patients benefitted by the first Syncona 38% inception (2
Slide 7: Found and Build
Found and Build
Slide 8: What do we look for in a scientific asset?
What do we look for in a scientific asset? Globally leading Intellectual Technology academics Property Transformational efficacy Defined, commercial Opportunity to develop for patients in areas of lead programme with pipeline differentiated platform high unmet need potential or no incumbent Therapeu
Slide 9: Our approach to company creation and development
Our approach to company creation and development Translating technology to products to reach full value potential Our partnership approach provides a strategic premium Approach key opinion leaders in the space Work with key opinion leaders to leverage their differentiated scientific insight into com
Slide 10: Focus on founding companies
Focus on founding companies Company Founded Syncona majority by Syncona ownership position Optimises strategy, control, ownership and returns Largest investor (27%) Largest investor (48%) Strategy: ensure company targets products that can credibly be taken to approval / market Largest investor (34%)
Slide 11: Sourcing technology in growing areas has led to multiple companies
Sourcing technology in growing areas has led to multiple Syncona companies and investments \\\\ \\\\ \\\\ \\\\\\\\\\\\\\\\\ \\\\\\\\\\\\\\\\\ \\\\\\ Cell therapy: T-cell biology & Gene therapy: companies covering the Radiotherapy companies immuno-oncology key tissue compartments covering key cell ty
Slide 12: Syncona platform: a growing competitive advantage
Syncona platform: a growing competitive advantage Platform enables rapid translation of basic scientific research into companies with the potential to be global leaders - Ability to identify a compelling new - Increased capability, expertise and network to area of science where a support company bui
Slide 13: Fund
Fund
Slide 14: Balance sheet strength is strategic and a key differentiator
Balance sheet strength is strategic and a key differentiator Life science companies requires significant Strong capital base is central to delivery of strategy and provides competitive capital as they scale advantage - Founding investors have the best ability to set strategy Syncona capital base - L
Slide 15: Market Context
Market Context
Slide 16: The promise of precision medicine
The promise of precision medicine Enables faster development, smaller, more capital efficient clinical trials and targeted commercial roll-out 30-60% A traditional drug may only be 30- 60% effective* ‒ Traditional drug development can lead to ineffective drug development; it assumes all patients res
Slide 17: Third Wave therapies have strong momentum
Third Wave therapies have strong momentum Syncona has established a leadership position in gene and cell therapy 10k monogenic diseases, less 10 ‘Third Wave’ therapies than 50 with treatments approved in the US “First Wave’’ 1950’s Small Molecule “Second Wave’’ 10 ‘Third Wave’ programmes 8/10 Of Syn
Slide 18: Third Wave commercial context
Third Wave commercial context Platforms attract premiums Company description and Market size of Take-out price Premium number of clinical programmes lead programme on a global $bn % basis CNS gene Spinal muscular atrophy therapy company 1 clinical programme 23,500 $8.7bn 88% Liver gene Haemophilia A
Slide 19: Syncona portfolio review
Syncona portfolio review
Slide 20: A high conviction differentiated portfolio
A high conviction differentiated portfolio Gene therapy - £408m – 55% of portfolio - Globally leading gene therapy platform companies Enriched in cell and gene therapy offering the - Strategically assembled, world class companies backed by potential for cures for a range of intractable leading acade
Slide 21: Continued strong performance
Clinical stage Pre-clinical stage Drug discovery Continued strong 31 March 2020 value Net invested/ returned Valuation FX move 31 Dec 2020 value £m Valuation performance Portfolio company Ownership* % £m (Fair value) the period £m change in period £m ment £m (Fair value) basis (Fair value)** % of NA
Slide 22: Outlook and summary
Outlook and summary
Slide 23: Portfolio company outlook
Portfolio company outlook Strong momentum in the portfolio with near term catalysts Company Status of pipelines Next steps Four programmes in clinical trials - Progress on AUTO1 pivotal trial with data update in CY2022 - Initial data in Phase I/II AUTO4 and AUTO1/22 programmes CY2021 Two lead progra
Slide 24: Building a sustainable, scalable model
Building a sustainable, scalable model Delivering strong risk-adjusted returns for shareholders Rolling 10 year targets Current portfolio: 2012-21 10 15-20 High quality portfolio of High quality portfolio of leading life science leading life science companies companies Purespring 15 2-3 Portfolio co
Slide 25: Appendix
Appendix
Slide 26: Executing a differentiated strategy
Executing a differentiated strategy 10 year targets Capturing the out-return from commercialising Found Build Fund exceptional science 2-3 new portfolio Proactively source Leverage expertise and Scale ambitiously, maintain companies p.a. globally competitive science, track record using Syncona signi
Slide 27: An expert multi-disciplinary team
An expert multi- Our unique skill set disciplinary team Scientific Commercial Company creation Investment Investment committee Nigel Keen Martin Murphy 1,2 Chris Hollowood 1 Co-founder and Chairman Co-founder and CEO CIO FIET, FCA PhD PhD Purespring ‒ Commercial and company creation ‒ Scientific, co
Slide 28: Autolus Therapeutics
Autolus Therapeutics Applying a broad range of technologies to build Investment thesis a pipeline of precisely targeted T cell therapies - No CAR-T therapy approved for adult designed to better recognise and attack cancer ALL for patients - AUTO1 targets a differentiated safety Board Seat 1 Key mana
Slide 29: Freeline Therapeutics
Freeline Therapeutics Clinical-stage, fully integrated, next generation, Investment thesis systemic AAV gene therapy company Key management team - To deliver curative gene therapies that will Theresa Heggie, Chief Executive (formerly Head of CEMEA at transform patients’ lives. Alnylam Pharmaceutical
Slide 30: Gyroscope Therapeutics
Gyroscope Therapeutics Developing gene therapy beyond rare disease Investment thesis by understanding the immune system and the - Seeking to take application of gene role genetics play in a patient’s risk of Key management team therapy beyond rare diseases developing late stage AMD Khurem Farooq, Ch
Slide 31: Achilles Therapeutics
Achilles Therapeutics Key management team Differentiated cell therapy approach targeting Iraj Ali, Chief Executive (former Syncona Partner) Investment thesis solid tumours utilising Tumour Infiltrating Karl Peggs, Founder and Chief Medical Officer - TIL’s have shown convincing efficacy in Lymphocyte
Slide 32: SwanBio Therapeutics
SwanBio Therapeutics Developing leading-edge gene therapies to Investment thesis deliver dramatic clinical efficacy for the - Gene therapy has the potential be treatment of neurological diseases transformational in neurology14 - Lead programme targeting, AMN*, an Board Seat 2 (inc. Chair) Key manage
Slide 33: Quell Therapeutics
Quell Therapeutics Engineered cell therapy company addressing Investment thesis immune dysregulation Key management team - Current standard of care for prevention of solid organ transplant rejection is Iain McGill, CEO (formerly on the Executive Committee and as life-long immunosuppression which Hea
Slide 34: Anaveon Therapeutics
Anaveon Therapeutics Immuno-oncology company developing a Investment thesis selective IL-2 Receptor Agonist - Developing a selective IL-2 agonist with improved administration and tox burden Key management team - Wide potential utility across multiple Andreas Katapodis, Chief Executive and Founder (f
Slide 35: OMass Therapeutics
OMass Therapeutics Focused on structural mass spectrometry to Investment thesis discover novel medicines for immunological - Opportunity to build a drug discovery and genetic disorders platform employing a differentiated Modified Mass Spectrometry Key management team technology with the potential to
Slide 36: Resolution: harnessing the healing properties of macrophages
Resolution: harnessing the healing properties 1 Extract monocytes1 3 Administer enhanced of macrophages from patients’ macrophages to blood patients Macrophage cells are a key immune cell type Based on the research of Prof. Stuart Forbes and Prof. John Campbell from the University of Edinburgh Built
Slide 37: Purespring: one of the first kidney AAV gene therapy companies
Purespring: one of the first kidney AAV gene therapy companies New Syncona company in area of deep domain expertise Syncona identified Engaged with world leading Worked with Prof Saleem Source 2019 opportunity to apply gene therapy to KOL, Prof. Moin Saleem, University of Bristol to identify potenti
Slide 38: The Syncona Foundation
The Syncona Foundation Supporting excellent charities that are meeting pressing needs within society, particularly those that are related to healthcare systems Focused on cancer, neuro-degenerative diseases, £31m Donations since 2012 gene therapy. Alongside other health and society related areas inc
Slide 39: Footnotes and sources
1. Syncona investment team analysis of key risks facing the companies; the companies are subject to other known and unknown risk s, uncertainties and other factors 2. Syncona investment team analysis of lead programmes in this area, indicative only 3. Source: Autolus – see Autolus corporate presenta